Chikungunya future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 13: | Line 13: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" | Assay type | | style="padding: 5px 5px; background: #DCDCDC;" | Assay type | ||
| style="padding: 5px 5px; background: #F5F5F5;" |In vitro (vero cells) | | style="padding: 5px 5px; background: #F5F5F5;" |''In vitro'' (vero cells) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Human | | style="padding: 5px 5px; background: #F5F5F5;" |Human | ||
| style="padding: 5px 5px; background: #F5F5F5;" |In vitro (vero cells) | | style="padding: 5px 5px; background: #F5F5F5;" |''In vitro'' (vero cells) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |In vitro (vero and primary human fibroblast cells) | | style="padding: 5px 5px; background: #F5F5F5;" |''In vitro'' (vero and primary human fibroblast cells) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |In vitro (BHK21 cells) | | style="padding: 5px 5px; background: #F5F5F5;" |''In vitro'' (BHK21 cells) | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" | Hypothesized target | | style="padding: 5px 5px; background: #DCDCDC;" | Hypothesized target | ||
| Line 27: | Line 27: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" | Advantages | | style="padding: 5px 5px; background: #DCDCDC;" | Advantages | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | In vitro study proved that it blocks the production of proinflammatory cytokines and the proliferation of | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | monocytes, macrophages, and lymphocytes | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Faster resolution of joint and soft tissue manifestations. | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Showed a significant inhibition of CHIKV at a low concentration. | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Well-tolerated with minimal side effects | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Minimal cytotoxicity | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" | Disadvantages | | style="padding: 5px 5px; background: #DCDCDC;" | Disadvantages | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | In vivo study required. | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Involvement of a small number of patients and lack of planning as randomly distributed patients were not | ||
compared with a placebo group. | |||
| style="padding: 5px 5px; background: #F5F5F5;" | The antiviral activity has been difficult to replicate in vivo. | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Not tested in in vivo system. | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Not tested in in vivo system. | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
|- | |- | ||
| style="padding: 5px 5px; background: #FFF;" colspan="6"| <SMALL>Table adapted from </SMALL> | | style="padding: 5px 5px; background: #FFF;" colspan="6"| <SMALL>Table adapted from </SMALL> | ||
Revision as of 18:21, 18 June 2014
|
Chikungunya Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Chikungunya future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Chikungunya future or investigational therapies |
|
Risk calculators and risk factors for Chikungunya future or investigational therapies |
Future Therapies
| Chloroquine | Ribavirin | 6-Azauridine | Arbidol | Harringtonine | |
|---|---|---|---|---|---|
| Assay type | In vitro (vero cells) | Human | In vitro (vero cells) | In vitro (vero and primary human fibroblast cells) | In vitro (BHK21 cells) |
| Hypothesized target | Disrupted endosome-mediated CHIKV internalization, possibly through the prevention of endosomal acidification. | Can interact with the intracellular viral RNA production. | Inhibition of orotidine monophosphate decarboxylase, an enzyme involved in the de novo biosynthesis of pyrimidine, cytidine, and thymidine. | Inhibition of virus mediated fusion and blocking of the viral entry into the target cells through inhibition of glycoprotein conformational changes that are essential for the fusion process. | Affects CHIKV RNA production inside the infected cell as well as viral protein expression such as the nsP3 and the E2 proteins. |
| Advantages | In vitro study proved that it blocks the production of proinflammatory cytokines and the proliferation of
monocytes, macrophages, and lymphocytes |
Faster resolution of joint and soft tissue manifestations. | Showed a significant inhibition of CHIKV at a low concentration. | Well-tolerated with minimal side effects | Minimal cytotoxicity |
| Disadvantages | In vivo study required. | Involvement of a small number of patients and lack of planning as randomly distributed patients were not
compared with a placebo group. |
The antiviral activity has been difficult to replicate in vivo. | Not tested in in vivo system. | Not tested in in vivo system. |
| Table adapted from | |||||